^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    UAB30

    i
    Other names: 9cUAB30, UAB30, UAB-30, UAB 30, (9Z)-UAB-30
    Associations

    News

    Trials
    Company:
    UAB University - Birmingham
    Drug class:
    Retinoid X receptor agonist
    Related drugs:
    Associations

    News

    Trials
    2ms
    Modeling Epithelial Homeostasis and Perturbation in Three-Dimensional Human Esophageal Organoids. (PubMed, Biomolecules)
    In the HOME0-grown organoids, IL-13 and UAB30 induced epithelial changes reminiscent of basal cell hyperplasia, a common histopathologic feature in broad esophageal disease conditions including eosinophilic esophagitis. HOME0 allows modeling of the homeostatic differentiation gradient and perturbation of the human esophageal epithelium while permitting a comparison of organoids from mice and other organs grown in ADF-based media.
    Journal
    |
    EGF (Epidermal growth factor) • TGFB1 (Transforming Growth Factor Beta 1) • IL13 (Interleukin 13)
    |
    UAB30
    6ms
    Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
    P1, N=27, Terminated, National Cancer Institute (NCI) | N=39 --> 27 | Active, not recruiting --> Terminated; Inadequate Accrual Rate
    Enrollment change • Trial termination
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • ER negative
    |
    UAB30
    11ms
    A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, University of Alabama at Birmingham | N=84 --> 0 | Trial completion date: Aug 2025 --> Aug 2023 | Recruiting --> Withdrawn | Trial primary completion date: Aug 2024 --> Aug 2023
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    CCND1 expression
    |
    UAB30
    1year
    Retinoid X receptor agonists enhances type I systemic and intratumoral immunity, but enhanced tumor prevention, with the HER2-IGFBP2-IGF1R plasmid vaccine in two mouse mammary tumor models (SITC 2023)
    Background Bexarotene and 9cUAB30 are oral retinoid X receptor (RXR) agonists which inhibit proliferation in breast cancer. There was no evidence by IHC of antigen expression loss with sequential RXR agonist with the vaccine. Conclusions The RXR agonists have an immunostimulatory role with plasmid cancer vaccines, but further modification of the immune environment may be needed for prevention vaccines.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • CSF2 (Colony stimulating factor 2) • FOXP3 (Forkhead Box P3) • IGFBP2 (Insulin-like growth factor binding protein 2)
    |
    Targretin oral (bexarotene oral) • UAB30
    1year
    A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer (clinicaltrials.gov)
    P1/2, N=84, Recruiting, University of Alabama at Birmingham | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2024
    Trial completion date • Trial primary completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • ATM (ATM serine/threonine kinase) • CD8 (cluster of differentiation 8) • CCND1 (Cyclin D1) • RAD51 (RAD51 Homolog A) • CD4 (CD4 Molecule) • CHEK1 (Checkpoint kinase 1) • IL10 (Interleukin 10) • CASP3 (Caspase 3) • FOXP3 (Forkhead Box P3) • PCNA (Proliferating cell nuclear antigen) • IL22 (Interleukin 22) • GABRP (Gamma-Aminobutyric Acid Type A Receptor Subunit Pi)
    |
    BCL2 expression • CD8 expression • CCND1 expression • CD4 expression • FOXP3 expression • PCNA expression
    |
    UAB30
    over1year
    Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2023 --> Jun 2024
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CASP3 (Caspase 3)
    |
    ER positive • ER negative
    |
    UAB30
    almost2years
    Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2023 --> Jun 2023
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CASP3 (Caspase 3)
    |
    ER positive • ER negative
    |
    UAB30
    2years
    A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer (clinicaltrials.gov)
    P1/2, N=84, Recruiting, University of Alabama at Birmingham | Trial completion date: Aug 2022 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Aug 2023
    Trial completion date • Trial primary completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • ATM (ATM serine/threonine kinase) • CD8 (cluster of differentiation 8) • CCND1 (Cyclin D1) • RAD51 (RAD51 Homolog A) • CD4 (CD4 Molecule) • CHEK1 (Checkpoint kinase 1) • IL10 (Interleukin 10) • CASP3 (Caspase 3) • FOXP3 (Forkhead Box P3) • PCNA (Proliferating cell nuclear antigen) • IL22 (Interleukin 22) • GABRP (Gamma-Aminobutyric Acid Type A Receptor Subunit Pi)
    |
    BCL2 expression • CD8 expression • CCND1 expression • CD4 expression • FOXP3 expression • PCNA expression
    |
    UAB30
    over2years
    Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
    P1, N=38, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Jun 2022
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CASP3 (Caspase 3)
    |
    ER positive • ER negative
    |
    UAB30
    over2years
    Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
    P1, N=41, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2022 --> Dec 2022 | Trial primary completion date: Feb 2022 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CASP3 (Caspase 3)
    |
    ER positive • ER negative
    |
    UAB30
    almost3years
    Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CASP3 (Caspase 3)
    |
    ER positive • ER negative
    |
    UAB30
    3years
    Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
    P1, N=45, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Clinical • Trial suspension
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • ER negative
    |
    UAB30
    over3years
    Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Jul 2021 --> Feb 2022
    Clinical • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • ER negative
    |
    UAB30
    over3years
    Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Apr 2021 --> Jul 2021
    Clinical • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • ER negative
    |
    UAB30
    over3years
    Novel second-generation rexinoid induces growth arrest and reduces cancer cell stemness in human neuroblastoma patient-derived xenografts. (PubMed, J Pediatr Surg)
    6-Me decreased oncogenicity and reduced cancer cell stemness of neuroblastoma PDXs, warranting further exploration of 6-Me as potential novel therapy for neuroblastoma.
    Clinical • Journal
    |
    SOX2 • POU5F1 (POU Class 5 Homeobox 1) • NANOG (Nanog Homeobox)
    |
    CD133 expression
    |
    UAB30
    over3years
    Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Feb 2022 --> Apr 2021
    Clinical • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • ER negative
    |
    UAB30
    4years
    A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer (clinicaltrials.gov)
    P1/2, N=84, Recruiting, University of Alabama at Birmingham | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • ATM (ATM serine/threonine kinase) • CD8 (cluster of differentiation 8) • CCND1 (Cyclin D1) • IFNG (Interferon, gamma) • RAD51 (RAD51 Homolog A) • CD4 (CD4 Molecule) • CHEK1 (Checkpoint kinase 1) • IL10 (Interleukin 10) • CASP3 (Caspase 3) • FOXP3 (Forkhead Box P3) • PCNA (Proliferating cell nuclear antigen) • IL22 (Interleukin 22)
    |
    BCL2 expression • CD8 expression • CCND1 expression • CD4 expression • FOXP3 expression • PCNA expression
    |
    UAB30
    4years
    [VIRTUAL] Novel Second Generation Rexinoid Reduces Cancer Cell Stemness in Human Neuroblastoma Patient-Derived Xenografts (ACS-CLINCON 2020)
    6-Methyl-UAB30 decreased oncogenicity and reduced cancer cell stemness of human neuroblastoma PDXs. These findings warrant further exploration of 6-Me as potential novel therapy for high-risk neuroblastoma.
    Clinical
    |
    SOX2 • POU5F1 (POU Class 5 Homeobox 1)
    |
    UAB30
    4years
    9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts. (PubMed, Transl Oncol)
    The ability to form tumorspheres and mRNA abundance of known stemness markers were also significantly decreased following treatment with UAB30, further indicating decreased cancer cell stemness. These results provide evidence that UAB30 decreased tumorigenicity and cancer cell stemness in neuroblastoma PDXs, warranting further exploration as therapy for high-risk neuroblastoma.
    Clinical • Journal
    |
    UAB30
    over4years
    Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
    P1, N=40, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
    Clinical • Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • ER negative
    |
    UAB30
    over4years
    Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
    P1, N=40, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Clinical • Trial suspension
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • ER negative
    |
    UAB30